Podcasts about pharmaceuticals

Merck Serono S.A. v. TWi Pharmaceuticals, Inc.

This episode was recorded at the 2025 Petfood Forum in Kansas City, Missouri.  Austin begins with an overview of the Association of American Feed Control Officials (AAFCO). Their membership consists of all government officials in the US and other countries who are charged by law to regulate animal feed, including pet food, in their jurisdictions. Canada, Costa Rica, and the US all participate in AAFCO. In the US, animal feed regulation is an integrated food safety system with a partnership between state and federal regulators as well as FDA. AAFCO's ultimate goal is to harmonize animal feed regulation across all states and provide a level playing field for the industry. (8:14)He goes on to explain that AAFCO and FDA's Center for Veterinary Medicine had a long-standing MOU in place that outlined an ingredient approval pathway that ended on October 1, 2024. FDA chose not to renew that MOU to focus on improving their other regulatory pathways, the Food Additive Petition Process and the Generally Regarded as Safe (GRAS) Notice Program. The FDA also has a new Animal Food Ingredient Consultation Process for ingredient approval. AAFCO has partnered with Kansas State University's Olathe Innovation Campus to scientifically review new ingredients, then bring them back through the AAFCO process to get formal approval. Ingredient companies can choose one of these four pathways for new ingredient approval. (10:05) Dr. Starkey notes that the process a company chooses will depend on the ingredient. If it's similar to ingredients proven safe on the market already, the KSU-AAFCO system would be a good route. If it's something a little more sophisticated or a new chemical, that may be more appropriate for a food additive petition, where toxicology studies would be conducted. (12:49)The panel discusses how scrutiny of GRAS rules might impact the pet food industry. Dr. Larson explains the scientific rigor involved in evaluating new ingredients. Dr. Starkey notes that there are different levels of GRAS, one of which is self-affirmed, which might be the one under the most scrutiny at this point. The panel agrees that transparency is critical for consumer confidence and ensuring health and safety of pets. (15:47)Austin talks about some of the ripple effects of the federal reduction in force in the regulatory arena. He and Dr. Larson talk about how the AAFCO-K-State partnership came to be, how K-State is ramping up to manage this project, and future plans for the partnership. (19:52)Dr. Starkey underlines the importance of timely ingredient approvals and how the new AAFCO-K-State partnership allows for companies to be more competitive due to the speed of approvals. Austin notes that an ideal submission with no follow-up questions or back-and-forth would have taken about 18 months to get approval under the old MOU between AAFCO and FDA, and a very small percentage of applications would be considered ideal. With the new AAFCO-K-State process, an expert panel reviews the submission in 60-90 days and the entire approval process is cut roughly in half, to about nine months. (25:55)Scott and the panel discuss how approval pathways differ for ingredient approval based on the claim being made. For example, is it a nutrient or is there some sort of pharmaceutical claim? (28:36)Panelists share their take-home thoughts. (37:19)Please subscribe and share with your industry friends to invite more people to join us at the Real Science Exchange virtual pub table.  If you want one of our Real Science Exchange t-shirts, screenshot your rating, review, or subscription, and email a picture to anh.marketing@balchem.com. Include your size and mailing address, and we'll mail you a shirt.

“Very often, doctors try to suppress what they feel or don't even have the vocabulary to describe their emotions,” says Professor Alicja Galazka of the University of Silesia, an observation based on decades of work with physicians to enhance their emotional intelligence and resilience. Galazka, a psychotherapist, psychologist, lecturer and coach, believes this deficit is rooted in part in a lack of instruction in the internal and external psychological dimensions of being a medical provider. “There is not enough space created in medical school for teaching and training students about how to deal with their own stress and all of the skills connected to building relationships with patients,” she tells host Michael Carrese. Those same skills are also critical to working effectively as a member of a care team, which is an increasingly common arrangement in hospitals and clinics. Galazka employs simulations, dramatic role-playing, mindfulness, Acceptance and Commitment Therapy and other methods in her work with an eye on increasing the emotional agility and sensitivity of her trainees and clients. Tune in to this thoughtful episode of Raise the Line to hear Galazka's ideas on how to reshape medical training, why she is a proponent of narrative medicine, and the merits of embedding psychologists on care teams as a resource for both patients and providers. Mentioned in this episode:University of SilesiaInternational Association of Coaching Institutes If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

Andrew and Tom discuss Trump's threat of 50% tariffs on copper and 200% on pharmaceuticals, the EU trade deal is ready to be signed, and Apple is losing executives. For information on how to join the Zoom calls live each morning at 8:30 EST, visit:https://www.narwhal.com/blog/daily-market-briefingsPlease see disclosures:https://www.narwhal.com/disclosure

Tariffs are on-again, off-again, but the most recent news we have is that President Trump is proposing a 50% tariff on copper and a whopping 200% tariff on pharmaceuticals. Greg and Holly discuss the recent developments and the impacts these tariffs could have.

Pharmaceuticals, one of Australia’s biggest US exports, might be slapped with 200 per cent tariffs; Millions of Qantas customers are being informed what data criminals stole from them; Trump again meets with Israeli Prime Minister Benjamin Netanyahu over Gaza; The death toll from the Texas floods has risen to 109; Kate Middleton attended a state banquet at Windsor Castle in honor of French President Emmanuel Macron. The Quicky is the easiest and most enjoyable way to get across the news every day. And it’s delivered straight to your ears in a daily podcast so you can listen whenever you want, wherever you want...at the gym, on the train, in the playground or at night while you're making dinner. Support independent women's media CREDITS Host/Producer: Cassandra Green Audio Production: Lu HillBecome a Mamamia subscriber: https://www.mamamia.com.au/subscribeSee omnystudio.com/listener for privacy information.

Gigi Robinson grew up with Ehlers-Danlos syndrome, a disease that turns your joints into overcooked spaghetti. Instead of letting it sideline her, she built a career out of telling the truth about invisible illness. We talk about what it takes to grow up faster than you should, why chronic illness is the worst unpaid internship, and how she turned her story into a business. You'll hear about her days schlepping to physical therapy before sunrise, documenting the sterile absurdity of waiting rooms, and finding purpose in the mess. Gigi's not interested in pity or polished narratives. She wants you to see what resilience really looks like, even when it's ugly. If you think you know what an influencer does, think again. This conversation will challenge your assumptions about work, health, and what it means to be seen.RELATED LINKSGigi Robinson Website: https://www.gigirobinson.comLinkedIn: https://www.linkedin.com/in/gigirobinsonInstagram: https://www.instagram.com/itsgigirobinsonTikTok: @itsgigirobinsonA Kids Book About Chronic Illness: https://akidsco.com/products/a-kids-book-about-chronic-illnessFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Go to https://cozyearth.com and use code HUMANHR for 40% off their best-selling sheets, pajamas, towels, and more. And if you get a post-purchase survey? Let them know you heard about Cozy Earth right here.In this episode, Traci Chernoff interviews Steven Swan, CEO of the Swan Group Executive Search Firm, discussing the evolving landscape of recruiting, particularly the influence of AI. They explore the balance between speed and quality in recruitment, the importance of human connection, and the advantages of external recruiting. Steven shares insights on crafting effective resumes and the purpose behind his podcast, emphasizing the need for emotional intelligence in decision-making during job changes.Chapters00:00 Introduction to Steve Swan and His Journey03:04 The Impact of AI on Recruiting06:02 Quality vs. Speed in Recruitment09:06 The Role of Human Connection in Recruitment12:00 The Advantages of External Recruiting15:11 Crafting Effective Resumes and LinkedIn Profiles17:56 The Purpose Behind the Podcast20:58 Advice for Aspiring Recruiters23:59 Navigating Job Changes and Emotional IntelligenceWe hope you enjoyed this episode with Steven Swan. If you found our discussion insightful, we'd like you to take a moment to rate our podcast. Your feedback helps us grow and reach more listeners who are passionate about these topics. You can also leave a review and tell us what you loved or what you'd like to hear more of - we're all ears!Don't forget to rate, review, and subscribe! Plus, leave a comment if you're catching this episode on Spotify or YouTube.About Our Guest: Steve Swan stands at the helm of The Swan Group Executive Search Firm as its CEO and Principal, carving a niche in the Pharma/Biotech industries with a keen focus on IT. His fervor for industry insights and a knack for bridging the gap between top professionals and industry demands have been instrumental in elevating organizations and propelling careers forward.Steve helms the popular podcast “Biotech Bytes.” A show that offers a stage for dialogue with IT luminaries in Biotechnology and Pharmaceuticals. Each episode delves into the minds of industry trailblazers, unpacking best practices and strategies that shape the life sciences realm. Steve's academic background in Psychology has helped him to understand both parties' deeper needs and motivations which is paramount to delivering candidates who become long-term  assets to the company. At the core of The Swan Group's philosophy is the ability to discern and fulfill what success means for both candidates and clients. Outside of work, Steve, once an avid mountain bike racer, has reignited his passion for cycling and aspires to traverse the U.S. on  two wheels. He lives in New Jersey with his wife and two daughters.Connect with Steven Swan here:LinkedIn: https://www.linkedin.com/in/swangroup/ Website: https://swangroup.net/ Connect with Traci here: ⁠https://linktr.ee/HRTraci⁠Disclaimer: Thoughts, opinions, and statements made on this podcast are not a reflection of the thoughts, opinions, and statements of the Company by whom Traci Chernoff is actively employed.Please note that this episode may contain paid endorsements and advertisements for products or services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this episode.

Thanks to our Partners, NAPA Auto Care and NAPA TRACS Recorded at the TST Big Event, John Anello passionately advocates for holistic health and nutrition, drawing from personal experiences and research. He shares practical tips on balanced eating, the power of natural, unprocessed foods like homemade beet juice, and the benefits of exercise and lifestyle choices for longevity and disease prevention. The conversation sheds light on common health challenges in the automotive industry and encourages listeners to take charge of their well-being through regular health monitoring, proactive self-care, and informed dietary decisions. Show Notes Watch Full Video Episode TST Big Event 2025: https://www.tstseminars.org/ Introduction (00:00:00) John's Background and Early Health Observations (00:01:56) COVID-19 as a Catalyst for Health Focus (00:05:56) Observations in Automotive Shops (00:07:43) Proactive Health Diagnostics (00:09:25) Body Aging, Stress, and Diet Fundamentals (00:13:34) Moderation and Understanding Nutrition (00:15:01) Cholesterol, Brain Health, and Immune Chicken Recipe (00:16:26) Supplements, Sunlight, and Exercise (00:24:12) Medication, Longevity, and Statins (00:26:26) Meal Prep, Containers, and Italian Diet (00:29:01) Sugar, Diabetes, and Electric Food (00:30:47) Discipline, Regimen, and Sleep (00:35:51) Organic Food, Farming Practices, and Minerals (00:38:01) Detoxing, Chemical Exposure, and Testing (00:41:01) Doctors, Pharmaceuticals, and Personal Choice (00:42:58) Dental Health and Natural Remedies (00:43:52) Thanks to our Partners, NAPA Auto Care and NAPA TRACS Learn more about NAPA Auto Care and the benefits of being part of the NAPA family by visiting https://www.napaonline.com/en/auto-care NAPA TRACS will move your shop into the SMS fast lane with onsite training and six days a week of support and local representation. Find NAPA TRACS on the Web at http://napatracs.com/ Connect with the Podcast: Follow on Facebook: https://www.facebook.com/RemarkableResultsRadioPodcast/ Join Our Virtual Toastmasters Club: https://remarkableresults.biz/toastmasters Join Our Private Facebook Community: https://www.facebook.com/groups/1734687266778976 Subscribe on YouTube: https://www.youtube.com/carmcapriotto Follow on LinkedIn: https://www.linkedin.com/in/carmcapriotto/ Follow on Instagram:

Professors Daniel Carpenter and Timo Minssen explore evolving pharma and medical device regulation, including the role of clinical trials, while Microsoft applied scientist Chad Atalla shares where AI governance stakeholders might find inspiration in the fields.Show notes: https://www.microsoft.com/en-us/research/podcast/ai-testing-and-evaluation-learnings-from-pharmaceuticals-and-medical-devices/

Wristband that provides relief for upper limb tremor is approved; FDA warns of clinically significant weight loss in younger kids taking ADHD meds; REMS removed for CAR T-cell immunotherapies; treatment approved for lung cancer patients with EGFR exon20 insertion mutations; and CDC committee recommends removing preservative from flu vaccines.

In this Huberman Lab Essentials episode, I explore major depression, including its underlying biology and discuss science-based approaches to alleviate symptoms and improve mood. I describe the wide-ranging symptoms of depression and explain how key neurotransmitters, hormones, stress, genetics and inflammation contribute to its development and persistence. I also cover treatment options, from traditional classes of antidepressant medications to emerging therapies such as ketamine and psilocybin. Finally, I highlight lifestyle-based tools, including exercise, supplementation and dietary strategies that can help manage depressive symptoms and promote mental well-being. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman BetterHelp: https://betterhelp.com/huberman Our Place: https://fromourplace.com/huberman Timestamps 00:00:00 Major Depression 00:01:10 Depression Symptoms 00:06:14 Sponsor: BetterHelp 00:07:33 Pharmaceuticals for Depression, SSRIs; Norepinephrine, Dopamine & Serotonin 00:14:33 Thyroid Hormone, Cortisol, Stress & Depression, Menstrual Cycle, Genetics 00:17:43 Sponsor: AG1 00:19:20 Increase Norepinephrine, Tools: Deliberate Cold Exposure & Exercise 00:21:40 Chronic Inflammation & Depression, Tools: Omega-3s (EPA) & Exercise 00:26:49 Sponsor: Our Place 00:28:41 Tool: Creatine Monohydrate Supplementation & Improving Depression 00:30:20 Novel Depression Therapies, Ketamine, Psilocybin 00:35:29 Ketogenic Diet & Refractory Depression, GABA 00:37:57 Recap & Key Takeaways Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode Description:If you've ever wondered what happens when a Bronx-born pediatric nurse with stage 4 colon cancer survives, raises a kid, becomes a policy shark, and fights like hell for the ignored, meet Vanessa Ghigliotty. She's not inspirational. She's a bulldozer. We go way back—like pre-Stupid Cancer back—when there was no “young adult cancer movement,” just a handful of pissed-off survivors building something out of nothing. This episode is personal. Vanessa and I built the plane while flying it. She fought to be heard, showed up in chemo dragging her kid to IEP meetings, and never stopped screaming for the rest of us to get what we needed. We talk war stories, progress, side-eyeing advocacy fads, TikTok activism, gatekeeping, policy wins, and why being loud is still necessary. And yeah—she's a damn good mom. Probably a better one than you. You'll laugh. You'll cry. You'll want to scream into a pillow. Come for the nostalgia. Stay for the righteous anger and iced coffee.RELATED LINKSVanessa on LinkedInColorectal Cancer Alliance: Vanessa's StoryZenOnco Interview with VanessaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

US equity futures are higher with S&P up 0.4%. US 10-year and 2-year yield both point down . Dollar softer versus yen, slightly firmer elsewhere. Oil down ahead of another expected OPEC and production hike. Gold firmer. Industrial metals higher. Asian equity markets are mixed. Nikkei has been outperforming to hit twelve month high. European markets are firmer. In trade developments, Canada to rescind digital services tax after Trump threatened to pull out of trade talks on Friday. Trump said he doesn't think he'll need to extend tariff 9-Jul deadline, contrasting somewhat with Treasury Secretary Bessent. Somewhat better news on US-China trade talks after both sides confirmed details on framework agreement where China relaxes rare earth exports and US removes countermeasures. Companies Mentioned: Torrent Pharmaceuticals, JB Chemicals & Pharmaceuticals, KKR, Avadel Pharmaceuticals

Health systems eligible for 340B savings must strike a balance by staying compliant with purchasing rules while also maximizing the amount of eligible savings they can obtain to invest in patient care. Angela Campitelli, the director of the pharmacy 340B program at MetroHealth System in Cleveland, explains how a hospital system such as hers implements a purchasing strategy that achieves that balance.Following rules for 340B purchasesDisproportionate share (DSH) hospitals, children's hospitals, and cancer hospitals are subject to a group purchasing organization (GPO) prohibition that bars them from buying covered outpatient drugs on GPO accounts. That requires maintaining a purchasing system that involves buying drugs at wholesale acquisition cost (WAC) for neutral inventory and then replenishing at 340B, WAC, or GPO pricing depending on how the drug is used.How the cycle can break downPurchasing drugs outside of the outlined processes could cause violations of the GPO prohibition or other 340B rules, which could lead to sanctions that might include losing eligibility for 340B. That is why health systems such as MetroHealth use staff education, regular auditing, and other safeguards to ensure they are purchasing and replenishing drugs on the correct accounts.Investments in the strategyCampitelli recommends 340B hospital teams bring their senior leadership on board to invest in auditing and other resources to ensure a strong purchasing strategy. Such investments will help avoid potential rule violations while ensuring that hospitals are not walking away from 340B savings to which they are entitled.Resources340B Health Appeals Rebate Ruling; Federal Court Agrees to Fast-Track Drugmaker Appeals

Bill Anderson was born in 1966 in Ohio, Texas and holds a bachelor's degree in chemical engineering from the University of Texas at Austin and a master's degree in management and chemical engineering from Massachusetts Institute of Technology (MIT). He already learned to take responsibility as a child and believes that every person is born with special talents and can grow up to do something “great” with personal abilities, skills and talents. His father also worked for a chemical company. Bill started his impressive career in 1989 as a process engineer for research and development at Ethyl Corporation in the Netherlands and Belgium. In 2023, he took over as CEO of Bayer. Bill is married and has three children.Bayer is a German-based life science company. The Company's segments are Crop Science, Pharmaceuticals and Consumer Health. The Crop Science segment focuses on seeds, improved plant traits, chemical and biological crop protection products, digital solutions and customer service for sustainable agriculture. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare. The Consumer Health segment develops, produces and markets nonprescription over-the-counter medicines. One of the best-known Bayer brands is Aspirin which is more than 100 years old.-----Want to hear something specific?(0:00) – Bill Anderson Introduction & Background(1:38) – Global Food Challenges & Bayer's Role(3:30) – Agricultural Productivity & Innovation(5:23) – Bureaucracy in Germany vs. Other Countries(7:50) – Monsanto Acquisition & Corporate Crisis(9:07) – Science Improving Lives(10:14) – Parkinson's Therapy Development(12:23) – Managing Global Challenges & Responsibility(14:03) – Mission-Driven Culture at Bayer(16:19) – Five Priorities for Transformation(18:13) – Cutting Bureaucracy & Driving Ownership(20:01) – Culture Change vs. Control(22:06) – Coaching & Empowering Employees(23:02) – Culture Eats Strategy for Breakfast(25:35) – EU Regulation & Sustainability Reporting(28:02) – Innovation & Privacy Challenges(29:05) – Microsoft Transformation as a Parallel(31:11) – Technology in Modern Farming(34:40) – Balancing Professional & Personal Life(43:20) – Reflections & Vision for Europe-----Willst du diese Folge nicht nur anhören, sondern Bill Anderson auch per Video sehen? Dann besuche gerne unserem YouTube Kanal: ⁠https://www.youtube.com/@followvoices⁠-----Folge VOICES auf Socials...▸ www – ⁠voices.fm⁠▸ Instagram – ⁠@followvoices⁠▸ YouTube – ⁠@followvoices⁠▸ LinkedIn – ⁠@marianne-heiß

Novo Nordisk end their partnership with Hims & Hers; update to Vizamyl labeling; autoinjector approved for pediatrics with lupus nephritis; psilocybin shows promise in treatment-resistant depression; sotatercept phase 3 trial results.

"Older adults have this special clarity about who they are and what they want, which is incredibly inspiring," says Dr. Julia Hiner, explaining, in part, why she loves her work as a geriatrician in Houston, Texas. She also enjoys the challenge of the medical complexity these patients present and the opportunity it creates to see the patient as a whole person. In fact, as you'll hear in this upbeat conversation with Raise the Line host Lindsey Smith, there's almost nothing about geriatrics that Dr. Hiner does not enjoy, which explains her passion for teaching the subject at McGovern Medical School at the University of Texas Health Science Center in Houston and trying to convince more students to pursue it as their specialty.  The need is great, given that there are only 8,000 geriatricians in the US despite a rapidly growing senior population. Tune in to learn why Dr. Hiner thinks clinicians avoid the field and the steps that can be taken to improve the situation, including requiring courses in geriatrics. You'll also learn about the importance of capacity assessments, the troubling, and under-reported, problem of elder mistreatment, ageism among health professionals and much more in this super informative episode. Mentioned in this episode:University of Texas Health Science Center at Houston McGovern Medical School  If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

Risa Arin doesn't just talk about health literacy. She built the damn platform. As founder and CEO of XpertPatient.com (yes, expert with no E), Risa's taking a wrecking ball to how cancer education is delivered. A Cornell alum, cancer caregiver, and ex-agency insider who once sold Doritos to teens, she now applies that same marketing muscle to helping patients actually understand the garbage fire that is our healthcare system. We talk about why she left the “complacent social safety” of agency life, how her mom unknowingly used her own site during treatment, what it's like to pitch cancer education after someone pitches warm cookies, and why healthcare should come with a map, a translator, and a refund policy. Risa brings data, chutzpah, and Murphy Brown energy to the conversation—and you'll leave smarter, angrier, and maybe even a little more hopeful.RELATED LINKS• XpertPatient.com• Risa Arin on LinkedIn• XpertPatient & Antidote Partnership• XpertPatient Featured on KTLA• 2024 Health Award BioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Check out the TIES Sales Showdown at www.tx.ag/TIESVisit The Sales Lab at https://thesaleslab.org and check out all our guests' recommended readings at https://thesaleslab.org/reading-listTo listen to The Sales Lab Podcast on your favorite apps, visit https://thesaleslab.simplecast.com/ and select your preferred method of listening.Connect with us on Facebook at https://www.facebook.com/saleslabpodcastConnect with us on Linkedin at https://www.linkedin.com/company/thesaleslabSubscribe to The Sales Lab channel on YouTube at  https://www.youtube.com/channel/UCp703YWbD3-KO73NXUTBI-Q 

What happens when you get everything you thought you wanted: money, women, cars and still feel empty?In this powerful conversation, entrepreneur and author Yousef Benhamida opens up about building a multi-million dollar business from nothing… and then losing it all emotionally, spiritually, and financially. We explore the *real* cost of chasing status, the trap of external validation, and what modern men are missing in their pursuit of "success."Whether you're a man who's grinding for the next level, or someone rethinking what you *actually* want, this conversation will challenge, provoke, and inspire.**CHAPTERS**00:00 Introduction00:40 Guest Introduction: Yusuf's Journey02:08 Yusuf's Early Ambitions and Influences02:54 The Reality of Owning a Ferrari03:30 Setting and Achieving Goals04:22 Cultural Influences on Desires05:36 The Flow Boy Concept06:05 Maturity and Self-Centered Desires07:17 The Value of Family and Intimacy08:01 The Trap of Material Desires11:36 The Illusion of Freedom and Self-Sabotage15:00 The Role of Money in Happiness15:56 Pharmaceuticals and Corporate Influence17:01 Concluding Thoughts: Finding Deeper Meaning

In this episode of EisnerAmper's Private Equity Dealbook, Elana Margulies-Snyderman, Director, Publications, EisnerAmper, speaks with Kapila Ratnam, Partner with the healthcare fund at NewSpring Capital, a Pennsylvania-based lower middle market private equity firm. She discusses some of the transactions NewSpring has completed in the pharmaceutical space, including Kincell Bio and Aerosafe Global. She walks us through the processes, along with both the opportunities and challenges faced when it came to those transactions. She also discusses the due diligence process on those deals and more.

Dr. Jamie Wells is back—and this time, she brought a book. We cover everything from biomedical design screwups to the glorified billing software known as the EHR. Jamie's new book, A Clinical Lens on Pediatric Engineering, is a masterclass in what happens when you stop treating kids like small, drunk adults and start designing medicine around actual human factors. We talk about AI in pediatric radiology, why drug repurposing might save lives faster than biotech IPOs, and the absurdity of thinking one-size-fits-all in healthcare still works.Jamie's a former physician, a health policy disruptor, a bioethicist, an MIT director, and a recovering adjunct professor. She's also a unicorn. We dig into the wonk, throw shade at bad design, and channel our inner Lisa Simpsons. This one's for anyone who ever wondered why kids' hospitals feel like hell and why “make it taste like bubblegum” might be the most important clinical innovation of all time. You'll laugh, you'll learn, and you might get angry enough to fix something.RELATED LINKSJamie Wells on LinkedInBook: A Clinical Lens on Pediatric Engineering (Amazon)Book on SpringerDrexel BioMed ProfileGlobal Blockchain Business CouncilJamie's HuffPost ArticlesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

After months of litigation in a federal district court, a key decision recently came out in the legal fight over 340B drug rebates. 340B Health Vice President of Legal and Policy Amanda Nagrotsky updates us on the development.Court deals a blow to drugmakersD.C. district court judge Dabney Friedrich ruled on May 15 that manufacturers cannot unilaterally implement rebate models for 340B, agreeing with the Health Resources & Services Administration (HRSA) that the agency effectively has preapproval authority over rebates. In her decision, the judge cited early results from a 340B Health survey finding that shifting 340B to a rebate model would divert significant hospital resources from patient care. Drugmakers have already appealed the ruling.Some bright spots for drugmakers in this decisionAlthough the decision largely went against pharmaceutical companies, the judge ruled that the 340B statute does not categorically prohibit rebates, leaving the door open for government approvals of rebates. The judge also agreed with drugmakers' assertions that HRSA should consider how rebate models could improve 340B compliance and how requiring the sharing of data through rebates could aid in drug company audits of covered entities.Will HRSA stop all rebates from proceeding?Despite this decision, the legal fight over rebates isn't over yet. The judge found that, for three of the manufacturers in these cases, HRSA has yet to issue final decisions with respect to their proposed rebate models. In the case of Sanofi, the judge found that HRSA failed to adequately explain the legal basis for rejecting the drugmaker's rebate model, and she directed the agency to reconsider its decision and explain whether and how it would violate the 340B statute. HRSA sent rebate guidance to the White House for approval earlier this month, though as of recording this episode it was not known what that guidance would say.ResourcesRead Our Analysis of the First Federal Court Decision on Rebates340B Health Continues Court Fight Against Rebates

In this episode of the Boost Your Biology podcast, Lucas Aoun interviews Camilla Thompson, an expert in health optimization and biohacking. Camilla shares her personal journey with mold toxicity, detailing her struggles with unexplained health issues and the pivotal moments that led her to biohacking as a means of reclaiming her health. The conversation explores the stealth symptoms of mold toxicity, the importance of proper mold inspection and removal, and effective detoxification strategies. Camilla emphasizes the foundational aspects of biohacking, including diet, hydration, and the benefits of intermittent fasting. The episode concludes with practical tips for listeners looking to improve their health and wellness. In this conversation, Lucas Aoun and Camilla discuss various aspects of biohacking, focusing on food responses, sleep optimization, the role of magnesium, and the importance of nutrition in health. They explore the limitations of the current medical system, the impact of pharmaceuticals, and advancements in preventative health technology. The discussion emphasizes the need for education and proactive health measures, as well as the growing interest in biohacking in Australia post-pandemicRelevant links:Camilla's IG: https://www.instagram.com/thewellnesscoach/?hl=en Check Out My Website For Coaching, Recommended Products and Much More:https://www.boostyourbiology.com/ Disclaimer:The information provided in this podcast episode is for entertainment purposes and is NOT MEDICAL ADVICE. If you have any questions about your health, contact a medical professional. This content is strictly the opinions of Lucas Aoun and is for informational and entertainment purposes only. It is not intended to provide medical advice or to take the place of medical advice or treatment from a personal physician. All viewers of this content are advised to consult with their doctors or qualified health professionals regarding specific health questions. Neither Lucas Aoun nor the publisher of this content takes responsibility for possible health consequences of any person or persons reading or following the information in this content. All consumers of this content especially taking prescription or over-the-counter medications should consult their physician before beginning any nutritional, supplement or lifestyle program.Chapters00:00 Introduction to Health Optimization01:03 Camilla's Journey with Mold Toxicity03:54 Identifying Mold Symptoms06:10 Mold Inspection and Removal08:05 Detoxification Strategies11:12 Biohacking Basics and Foundations12:51 Dietary Considerations for Health14:51 Hydration and Water Quality18:00 Daily Nutrition Essentials20:57 Intermittent Fasting and Mental Clarity23:04 Overcoming Challenges in Biohacking25:20 Exploring Food Responses and Biohacking26:40 The Importance of Sleep Optimization28:43 Understanding Magnesium and Its Effects29:39 Innovations in Sleep Technology31:38 Nutrition and Its Role in Health34:03 Rethinking the Medical System36:59 The Role of Pharmaceuticals in Health40:00 Advancements in Preventative Health Technology41:57 The Future of Biohacking in Australia Hosted on Acast. See acast.com/privacy for more information.

"It was pretty apparent to me that something was going on with him," says Kristi Levine, describing the realization that, based on her experience as a Montessori teacher, her infant son, Trey, was missing developmental milestones. Unfortunately, Kristi's hunch turned out to be correct and Trey was later diagnosed with a rare genetic mutation called CACNA1A which is impacting his motor skills, balance, coordination and speech. Kristi and her husband, Eric, join host Michael Carrese on this installment in our Year of the Zebraseries to help us understand the disorder and its implications for Trey and their family, which includes Trey's older sister Stella.  “There's a lot of guilt involved in being a parent of a child who has a disability because you never feel like you're doing enough,” shares Eric, even though they both work full time and have becoming experts at juggling work, caregiving, advocating, and volunteering with the CACNA1A Foundation. In this candid interview, Eric and Kristi discuss the challenges of parenting a child with complex medical needs, the importance of community support, the ongoing search for treatment options, and share some advice for clinicians caring for patients and families living with rare disorders. “We just want medical professionals to respect and understand what we're dealing with on a day-to-day basis and to see our kids holistically, and not just try to fix the problem medically. Understand that for us, the biggest thing that we want for our kids is just their quality of life.”Mentioned in this episode:CACNA1A Foundation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

What if the water in your home is doing more harm than good?In this episode, Neil sits down with Nelson, a U.S. manufacturer and founder of Sentry H2O, to unpack the dirty truth about most filtration systems and what clean water actually looks like in the 21st century.Nelson shares how his decades in product manufacturing led him to build a water filtration company that's not only beating cancer in his own life, but also helping animals live longer, supporting missionaries in Africa, and even getting attention from U.S. political leaders. In This Episode, We Cover:✅ Why Chinese suppliers are sneaking around tariffs and how to avoid their tactics✅ How American-made products are regaining global leverage✅ The toxic truth about “clean” water and what actually gets filtered✅ How Sentry H2O removes fluoride, heavy metals, pharmaceuticals, and nanoplastics✅ Why dogs, horses, and even fish live longer on this water✅ The founder's personal story of using oxygenated water to fight cancer✅ How you can test your water and get a system built specifically for your homeChapters:[00:01:02] Nelson's Background: 25+ Years in Manufacturing[00:02:20] How China Repackages Products to Dodge Tariffs[00:04:00] Why U.S. Manufacturing is Gaining Ground[00:08:03] What Sentry H2O Filters Out (Fluoride, VOCs, Pharmaceuticals, More)[00:14:02] Whole-Home System: From Dishwasher to Shower[00:16:22] Portable Filters Designed for Astronauts and Missionaries[00:18:00] How Nelson Used His Own Water System to Beat a Health Scare[00:23:01] Pets Prefer It: Dogs, Horses, and Even Fish[00:25:35] Use Code “NEIL” at SentryH2O.com for 10 Percent Off[00:27:44] Hydration, Alkalinity, and the Power of Clean Water 

Send us a textOn this week's WTR Small-Cap Spotlight, we speak with Apimeds CEO Erik Emerson about the newly NYSE listed company and the development of Apitox, a purified honeybee venom, for knee osteoarthritis and multiple sclerosis. We discuss the therapeutic properties of bee venom and the clinical/regulatory plans to bring Apitox to the US market. Listen to learn more about Apimeds and its novel approach to treat inflammatory pain.

Whether you've been served an advert for it, or just heard about it in the media, it's likely that 'Ozempic' isn't a totally unfamiliar word. Now often associated with weight-loss, Ozempic is actually the brand name for a drug used to treat diabetes. So what exactly is it, how does it work, and is it safe? We chat to diabetes and endocrinology (hormone) expert Dr Annie de Bray to find out.  

Erica Campbell walked away from corporate life, took a hard left from the British Embassy, and found her calling writing checks for families nobody else sees. As Executive Director of Pinky Swear Foundation, she doesn't waste time on fluff. Her team pays rent, fills gas tanks, and gives sick kids' parents the one thing they don't have—time. Then, breast cancer hit her. She became the patient. Wrote a book about it. Didn't sugarcoat a damn thing. We talk about parking fees, grief, nonprofit burnout, and how the hell you decide which families get help and which don't. Also: AOL handles, John Hughes, and letters from strangers that make you cry. Erica is part Punky Brewster, part Rosie the Robot, and part Lisa Simpson—with just enough GenX Long Island sarcasm to make it all land. This one sticks.RELATED LINKSPinky Swear FoundationThe Mastectomy I Always Wanted (Book)Erica on LinkedInThink & Link: Erica Campbell“Like the Tale of a Starfish” - Blog Post“Cancer Diagnosis, Messy Life, Financial Support” - Blog PostFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Subscribe to UnitedHealthcare's Community & State newsletter.Health Affairs' Rob Lott interviews Keith Drake of Greylock McKinnon Associates about his recent paper that explores trends in authorized generic drug launches and the effects observed on competition in pharmaceutical markets in the US. Order the June 2025 issue of Health Affairs.Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcast Subscribe to UnitedHealthcare's Community & State newsletter.

Peter Ordentlich, Chief Scientific Officer and Founder at Syndax Pharmaceuticals, a clinical oncology company, is focused on developing precision medicine approaches to treat cancer and chronic graft-versus-host disease. The menin protein plays a critical role in driving certain types of blood cancers, and the Synex therapy is a menin inhibitor that can disrupt this cancer-driving pathway. The platform is also developing an antibody addressing the unmet needs in cGVHD to reduce the disease-driving macrophages. Peter explains, "Syndax is a clinical oncology company, which means we're focused primarily on cancer, and we're primarily doing clinical development. We started the company really looking at resistance pathways to developing cancer, and we've been focused on two main areas. One in the indication space of leukemia, which are certain types of blood cancers, and that's with a program we have around the small molecule drug called revumenib. We are also focused in another area of diseases called chronic graft-versus-host disease. These are diseases that happen post-stem cell transplant, and there we're developing an antibody called axatilimab. And so those two programs are really what we've been focusing on for the last five or six years and have led to each of those drugs." "So menin is a very interesting protein, and basically what this is, it's called a scaffold protein. And you can imagine a scaffold, just something you build things upon. And so menin interacts with DNA through a variety of other factors, and you build on top of this a complex of other proteins that can turn genes on and off. And in the case of certain types of leukemias, the mutation that creates certain other cancer-causing proteins binds to menin. That's what drives certain genes that drive leukemia to always be turned on. And so what we've tried to do and others have tried to do is disrupt that interaction and essentially cause the scaffold to fall apart. And when that falls apart, you can no longer keep those genes on that drive leukemia, and instead, you have genes that essentially cause the cell to stop growing."  #SyndaxPharma #AcuteLeukemia #cGHVD #Oncology #PrecisionMedicine #Menin #MeninInhibitors syndax.com Download the transcript here

Peter Ordentlich, Chief Scientific Officer and Founder at Syndax Pharmaceuticals, a clinical oncology company, is focused on developing precision medicine approaches to treat cancer and chronic graft-versus-host disease. The menin protein plays a critical role in driving certain types of blood cancers, and the Synex therapy is a menin inhibitor that can disrupt this cancer-driving pathway. The platform is also developing an antibody addressing the unmet needs in cGVHD to reduce the disease-driving macrophages. Peter explains, "Syndax is a clinical oncology company, which means we're focused primarily on cancer, and we're primarily doing clinical development. We started the company really looking at resistance pathways to developing cancer, and we've been focused on two main areas. One in the indication space of leukemia, which are certain types of blood cancers, and that's with a program we have around the small molecule drug called revumenib. We are also focused in another area of diseases called chronic graft-versus-host disease. These are diseases that happen post-stem cell transplant, and there we're developing an antibody called axatilimab. And so those two programs are really what we've been focusing on for the last five or six years and have led to each of those drugs." "So menin is a very interesting protein, and basically what this is, it's called a scaffold protein. And you can imagine a scaffold, just something you build things upon. And so menin interacts with DNA through a variety of other factors, and you build on top of this a complex of other proteins that can turn genes on and off. And in the case of certain types of leukemias, the mutation that creates certain other cancer-causing proteins binds to menin. That's what drives certain genes that drive leukemia to always be turned on. And so what we've tried to do and others have tried to do is disrupt that interaction and essentially cause the scaffold to fall apart. And when that falls apart, you can no longer keep those genes on that drive leukemia, and instead, you have genes that essentially cause the cell to stop growing."  #SyndaxPharma #AcuteLeukemia #cGHVD #Oncology #PrecisionMedicine #Menin #MeninInhibitors syndax.com Listen to the podcast here

About this episode: Would it be a good idea to have tariffs on pharmaceuticals? In this episode: a conversation about the rationales for tariffs as well as potential downsides—like higher drug prices—and what could really help with supply and pricing issues. Guest: Dr. Mariana Socal studies the pharmaceutical market and is an associate professor in Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health. Host: Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: Tariffs as a Hidden Tax: Price Pass-Through in Multi-Stage Supply Chains—Johns Hopkins Carey Business School Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages—NBC Los Angeles Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Bryan Moskow: MS Organic & Biochemistry UCF/GT, PhD Student at Georgia Tech, Offseason/Prep Protocols & Hormone OptimizationThe Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder:[ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]https://transcendcompany.com/patient-intake-form/?ls=Nyle+NaygaWatch it: https://www.youtube.com/watch?v=6Ihq4tIzyS8&t=5618sRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.com00:00 - Intro01:47 - Steroids and PEDs in Bodybuilding  02:59 - Podcast Setup and Audio Talk  03:41 - Science Without an Agenda  04:22 - GLP-1 and GLP-300008:19 - Insulin, Diets, and Brain Health  10:26 - Berberine and Supplement Bioavailability  13:04 - Beta-Alanine and Sodium Bicarbonate  14:59 - Citing Studies and Research Quality  17:32 - Natural Alternatives to Pharmaceuticals  19:34 - Esters and Compound Solubility  21:29 - Brian's Bodybuilding Journey  24:56 - Steroid Protocols and Half-Lives  30:34 - PCT and Fertility Strategies  38:44 - HCG and Male Contraception  41:53 - SARMs and Their Risks  46:08 - GHB as a Supplement  47:40 - GHB Risks and College Stories  50:32 - Prescription GHB and GABA Dangers  51:48 - Long-Term Effects of Sleep Meds 

Kinsella on Liberty Podcast: Episode 467. I was asked one Juani (@witheredsummer), an Argentinian Voluntarist, on Twitter and then later via email, to review his draft article "Ideas Are Free: A Case Against Intellectual Property" (text below) (I note that perhaps ironically, this title is almost identical to one of my own previous publications/speeches, Ideas are Free: The Case Against Intellectual Property: or, How Libertarians Went Wrong). I told him it was too long for me to fisk, got Grok to analyze it (see below), and told him to read up on some of my work and review the analysis, so that we could have a more productive conversation about it, and which I could also at least record for my podcast. This is our discussion. In the end, he didn't really have many questions and I think he just wanted to vent about how bad IP is and express frustration at out outrageous and harmful it is. And suggest some ways to get through to people and propose reforms. Things I already knew and have been writing about for 30 years. He basically identifies many problems with and absurdities with IP law ... which he's right about and which I've mentioned ... and comes up with some proposals for IP reform that would reduce its harm. Again, which he's right about and which I and others have also proposed, but also which are unlikely to be adopted by those infested with the IP mind-virus. Not really sure what the point of this was, but here it is FWIW. https://youtu.be/AS-8mFZGfnI GROK SHOWNOTES: [0:00-15:00] In this episode of the Stephan Kinsella podcast (KOL467), host Stephan Kinsella engages with Juani from Argentina to discuss intellectual property (IP) and its implications, particularly in the context of artificial intelligence (AI). Juani, a programmer and self-described libertarian, shares his consequentialist critique of IP, influenced by Kinsella's work and his own essay, "Ideas for Free: A Case Against Intellectual Property." The conversation begins with Juani outlining his concerns about IP's practical harms, such as its impact on innovation and culture, and transitions into a discussion about AI. They explore how AI's reliance on vast datasets, often containing copyrighted material, raises legal questions about copying, authorship, and derivative works. Kinsella highlights the tension between copyright law and AI development, noting that current laws could stifle AI's potential by limiting data access or imposing costly licensing requirements. [15:01-1:37:33] The discussion deepens into specific examples of IP's negative effects, including cultural erasure through Disney's sanitized retellings of historical figures like Pocahontas and Mulan, and the economic burdens of pharmaceutical patents, which restrict access to life-saving drugs in poorer nations. Juani argues that IP acts as a form of censorship and reinforces wealth disparities, citing cases like patent trolling and the high cost of educational materials in developing countries. Kinsella agrees, emphasizing that IP distorts markets and innovation, and suggests that copyright's harm to AI development may rival its threat to internet freedom. Toward the end, Juani proposes a reform to replace IP exclusivity with a decaying royalty system, which Kinsella views skeptically, arguing that entrenched IP proponents will resist any reduction in rights. The episode concludes with reflections on piracy, the success of platforms like Steam, and the cultural shift toward viewing copying as less harmful, signaling a potential change in public perception of IP.   Youtube Transcript and detailed Grok shownotes below. Related: KOL466 | On IP Reform and Improving IP law FDA and Patent Reform: A Modest Proposal “Absurd Arguments for IP” “The Patent, Copyright, Trademark, and Trade Secret Horror Files” Boldrin & Levine on Covid-19, Vaccines, the Pharmaceutical Industry, and Patents Patents and Pharmaceuticals

Send us a textA critique of SSRIs and pharma's influence on medicine, including SSRI-induced sexual dysfunction, suicidality, and violence. Long Summary: Dr. David Healy critiques modern medicine, focusing on SSRIs and psychiatric medicine, including: how pharmaceutical companies manipulate clinical trial data, ghostwrite studies, and influence medical practice, often ignoring patient experiences; highlighting issues like post-SSRI sexual dysfunction (PSSD), the immediate sensory effects of SSRIs, and their potential to induce suicidal or violent behavior; challenging the reliance on randomized controlled trials (RCTs) over individual patient reports; and more.About the guest: David Healy, MD, PhD, a psychiatrist and pharmacologist, has decades of experience researching the serotonin system and SSRIs, working across Ireland, the UK, Canada, and the US. He is a professor at McMaster University and a vocal critic of pharmaceutical industry practices.Discussion Points:SSRIs cause near-immediate sensory effects, like genital numbing, in most people.Post-SSRI sexual dysfunction (PSSD) can persist for years or decades after stopping the drug, affecting many long-term users.Healy argues RCTs prioritize averages over individual experiences, often missing serious side effects like suicidality.Pharmaceutical companies ghostwrite studies and manipulate data, with journals like the New England Journal of Medicine publishing misleading articles.Serotonin theory of depression lacks evidence.Industry tactics include dismissing patient reports as anecdotes and using high doses in trials to mask weak efficacy.SSRIs can increase suicide risk, not just during initiation but also when adjusting doses or withdrawing, as seen in cases like the Aurora movie theater shooting.Regulatory bodies like the FDA often fail to investigate adverse effects due to bureaucratic processes and lack of follow-up.Healy emphasizes doctors' failure to prioritize patient observations, driven by industry-influenced standards of care.Related episode:M&M 88: Depression, Serotonin, SSRIs, Psychiatry & Social Media | Joanna Moncrieff*Not medical advice.Support the showAll episodes, show notes, transcripts, and more at the M&M Substack Affiliates: KetoCitra—Ketone body BHB + potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off any subscription (cancel anytime) Lumen device to optimize your metabolism for weight loss or athletic performance. Code MIND for 10% off Readwise: Organize and share what you read. 60 days FREE through link SiPhox Health—Affordable at-home blood testing. Key health markers, visualized & explained. Code TRIKOMES for a 20% discount. MASA Chips—delicious tortilla chips made from organic corn & grass-fed beef tallow. No seed oils or artificial ingredients. Code MIND for 20% off For all the ways you can support my efforts

Julio Martinez-Clark teamed up with his cardiologist brother and other doctors to help speed up the clinical trials part of the process. Julio's team at bioaccess® is moving medicine forward quicker by helping startups and researchers get the data from clinical trials in other countries. Advancements can now come to market quicker while also helping suffering people in countries that do not have the means to afford the proper medical care. This saves time, money, and people.Julio Martinez-Clark is the co-founder and CEO of bioaccess®. Julio believes Latin America is an untapped destination for Medtech clinical research. Since 2010, Julio has supported +100 Medtech in operationalizing successful clinical trials in several countries in Latin America. Julio was the chairman of the board of the Association for the Advancement of Clinical Research in Colombia (AVANZAR). Julio writes a column at Med Device Online, where his articles have been "Featured Editorials" on several occasions. Julio hosts the LATAM Medtech Leaders podcast, interviewing Medtech leaders who have succeeded in Latin America.Julio has a wealth of experience in various fields, including serving as an advisor to the CEO of Amavita Heart and Vascular Health™, the most extensive cardiovascular practice in South Florida, an advisor to government agencies in Colombia looking to position the country as a clinical trial destination, and a mentor to startups at Macondo Labs, a top incubator in Colombia.Learn more at www.bioaccessla.com and connect with Julio on Linkedin @juliomartinezclark Visit ConfidenceThroughHealth.com to find discounts to some of our favorite products.Follow me via All In Health and Wellness on Facebook or Instagram.Find my books on Amazon: No More Sugar Coating: Finding Your Happiness in a Crowded World and Confidence Through Health: Live the Healthy Lifestyle God DesignedProduction credit: Social Media Cowboys

Allyson with a Y. Ocean with two Ls. And zero chill when it comes to changing the face of cancer care. Dr. Allyson Ocean has been quietly—loudly—at the center of every major cancer breakthrough, nonprofit board, and science-backed gut punch you didn't know you needed to hear. In this episode, she joins me in-studio for a conversation two decades in the making. We talk twin life, genetics, mitochondrial disease, and why she skipped the Doublemint Twins commercial but still ended up as one of the most recognizable forces in oncology. We cover her nonprofit hits, from Michael's Mission to Let's Win Pancreatic Cancer to launching the American Jewish Medical Association—yes, that's a thing now. We get personal about compassion in medicine, burnout, bad food science, and microplastics in your blood. She also drops the kind of wisdom only someone with her résumé and sarcasm can. It's raw. It's real. It's the kind of conversation we should've had 20 years ago—but better late than never.RELATED LINKS:– Dr. Allyson Ocean on LinkedIn– Let's Win Pancreatic Cancer– NovoCure Leadership Page– Michael's Mission– American Jewish Medical Association– The POLG Foundation– Cancer Buddy App (Bone Marrow and Cancer Foundation)– Dr. Ocean at OncLiveFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

(June 03,2025)China's grip on the global pharmaceuticals industry is exposed by the Trump administration's tariff threat. Mosquitos could be driven to extinction with gene editing, but is that a good thing? 

In the fast-paced world of entrepreneurship, self-care often takes a backseat. This episode of Business Chop brings you Dr. Tamar Lawful, a distinguished pharmacist and CEO of Lyfe Balance Inc., who shares her journey from traditional pharmacy to advocating for holistic health and self-care.From Prescription Pads to Personalized Wellness Dr. Lawful's 21-year career in pharmacy took an unexpected turn when she realized that simply dispensing medications wasn't truly helping patients achieve lasting health. Her innovative approach now combines:Nutritional genomicsLifestyle modificationsPersonalized health coachingThe DNA Strategy: A Path to Sustainable Health Dr. Lawful introduces her three-phase DNA strategy for achieving a balanced, healthier lifestyle:Detox your mind from preconceived notions about healthNourish your body with tailored nutrition and exerciseAlign your actions with your health goalsNutrigenomics: Unlocking Your Body's Unique CodeLearn how Dr. Lawful uses genetic testing to create personalized nutrition and lifestyle plans. This cutting-edge approach helps clients:Understand their genetic predispositionsAddress root causes of health issuesAchieve lasting results beyond traditional methodsDr. Lawful emphasizes the importance of daily self-care practices, tailored to each individual's needs. Discover how small, consistent actions can lead to significant improvements in overall well-being and productivity.A Special Gift to Support Your Wellness Journey  As a Business Chop listener, you'll receive a complimentary $500 Nutrigenomic Test when you join the LYFE Balance 90-Day Health Coaching Program. Let's discover what your body needs—book your FREE consultaSend us a messageBuzzsprout - Let's get your podcast launched!Start for FREEDesignrr for eBooks, BlogsCreate eBooks, Blogs, Lead Magnets and more! Riverside.fm Your Own Virtual StudioProfessional Virtual StudioAltogether Domains, Hosting and MoreBringing your business online - domain names, web design, branded email, security, hosting and more.Digital Business CardsLet's speed up your follow up. Get a digital business card.Small Business Legal ServicesYour Small Business Legal Plan can help with any business legal matter.Mens and Womens HatsSince 1972, American Hat Makers has been dedicated to the art of fine hat making.Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the showWant to be a guest on Business Chop? Send Audrey Wiggins a message on PodMatch, here: podmatch.com/hostdetailpreview/audreywiggins Please Rate & ReviewTo work with Audrey schedule a breakthrough/discovery session.

تواصل معانا وشاركنا افكاركما الذي يدفع شخصًا ناجحًا للتخلي عن مهنة مرموقة في المصرفية الاستثمارية والمخاطرة بكل شيء في صناعة لا يملك فيها أي خبرة أو حتى شغف؟في هذه المحادثة الصريحة والعميقة، يكشف صلاح مؤنس، الرئيس التنفيذي والمؤسس المشارك لشركة كليو فارماسوتيكل، عن الرحلة غير التقليدية التي قادته من عالم التمويل إلى عالم مستحضرات التجميل والعناية الشخصية. بدايةً من كرسيين في مساحة عمل مشتركة إلى بناء واحدة من أكبر منصات التجارة الإلكترونية في مصر تشحن أكثر من 7000 وحدة يوميًا، قصة صلاح تتحدى المفاهيم التقليدية حول الشغف كشرط مسبق للنجاح.نستكشف معًا اللحظات الحاسمة في رحلته: من جذور خبرته في المصرفية الاستثمارية، إلى كيفية استخدامه لمهاراته في الإدارة المالية لبناء شركة تنمو ذاتيًا دون الحاجة لمستثمرين خارجيين، وكيف حوّلت الجائحة العالمية مسار الشركة بشكل جذري. يشارك صلاح بصراحة تامة التحديات الشخصية والمهنية التي واجهها، واستراتيجيات البقاء في سوق متقلب، وكيفية اختيار وبناء فريق عمل فعّال.سواء كنت رائد أعمال طموحًا، أو مهنيًا تفكر في تغيير مسارك الوظيفي، أو مهتمًا بفهم ديناميكيات نجاح الشركات الناشئة في أوقات الاضطراب الاقتصادي، ستجد في قصة صلاح مؤنس دروسًا قيمة ورؤى عملية يمكن تطبيقها في رحلتك الخاصة. اشترك الآن واستمع لهذه القصة الملهمة التي تثبت أن أعظم النجاحات قد تأتي من أكثر المنعطفات غير المتوقعة في حياتنا.Support the showرعاة بودكاست بزنس بالعربي:

Sponsored by Invivyd, Inc.Nobody wants to hear about COVID-19 anymore. Especially not cancer patients. But if you've got a suppressed immune system thanks to chemo, radiation, stem cell transplants—or any of the other alphabet soup in your chart—then no, it's not over. It never was. While everyone else is getting sweaty at music festivals, you're still dodging a virus that could knock you flat.In this episode, Matthew Zachary and Matt Toresco say the quiet part out loud: many immunocompromised people may not even know they have options beyond vaccines. Why? Because the system doesn't bother to tell them. So we're doing it instead. We teamed up with Invivyd to help get the word out about tools other than vaccines that can help prevent COVID-19. We break down the why, the what, and the WTF of COVID-19 risk for cancer patients and why every oncologist should be talking about this.No fear-mongering. No sugarcoating. Just two guys with mics who've been through it and want to make sure you don't get blindsided. It's fast, funny, and furious—with actual facts. You've got more power than you think. Time to use it.RELATED LINKSExpand Their OptionsInvivydMatt Toresco on LinkedInOut of Patients podcastFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Much like the popularity of methylene blue, the building popularity of nicotine pouches has produced a sort of health sub-culture within the larger context of a generally unhealthy population. Whereas methylene blue is relatively new to the public, nicotine has been around, and much more popular, for a lot longer. Sure, methylene blue has certain medical benefits, namely as a supplement for those with methemoglobinemia, though too much of the substance can cause the same condition. Though it goes with anything - quantity, quality, long term use, additional additives, and health context matter. The same goes for nicotine pouches. Nicotine, especially the non-smoked kind, can benefit cognition, memory, and concentration to a small degree, though delivery mechanisms and quality matter greatly.  Could it be that these recent health potions are nothing more than a commodifying and monetizing not only of health but of the healthcare revolution?The bottom line is this: Big Tobacco lied, obfuscated and killed for decades. By the 1980s and 1990s, studies, high profile cases, and lawsuits put some final nails in their coffin. It was around this time that these companies began to diversify heavily. Phillip Morris purchased General Foods, Kraft, and Miller Brewing in the 80s, and a little later Nabisco in 2000. R.J. Reynolds had purchased the same company in the 80s. They also had control of Pacific Hawaiian products since the 60s. These acquisitions allowed tobacco companies to apply cigarette marketing tactics, like targeting children and minorities, and to develop "hyper-palatable" foods high in fat, sugar, and sodium, influencing the U.S. food system for decades.Vaping was then introduced in the early 2000s and within a few years Big Tobacco was diversifying again. In 2014 MarkTen e-cigarettes were introduced by Altria (Phillip Morris) and Vuse was introduced by R.J. Reynolds (BAT). Soon after Altria introduced ON!, British American Tobacco (R.J. Reynolds) launched VELO, and Phillip Morris acquired ZYN. When vaping began to develop a bad reputation for some, the industry convinced many that cigarettes were the safer choice, while others kept vaping for the same reason.Although these companies had marketed nicotine gum and patches for decades, the market grew rapidly as people tried to stop smoking in general. But what about the market for non-smokers? Well, that's where ON!, ZYN, and VELO come in. Instead of chewing tobacco, cigarettes, patches or gum, pouches were for all non-smokers and promoted as having health benefits. By the time these pouches were largely under the control of Big Tobacco there began a campaign of promotion on social media, primarily TikTok, for flavored nicotine pouches - as with flavored cigarettes and vapes. Now they have been picked up by conservatives and those leaning in the direction of MAHA. It all makes sense, too, when considering what the HHS and NIH have done so far under RFK Jr. Although certain vaccines are longer advised for healthy kids and pregnant women, the HHS and NIH are investing millions, maybe billions, in “universal influenza and coronavirus vaccines.” With Project Stargate there is further investment in personalized medicine and vaccines, followed up in May, 2025, with three other interesting developments. May 5 saw the White House strip regulations for domestic pharmaceutical manufacturing and May 12 saw the White House authorize that “the Secretary of Health and Human Services (Secretary) shall facilitate direct-to-consumer purchasing programs for pharmaceutical manufacturers that sell their products to American patients at the most-favored-nation price." On May 19 the HHS posted about RFK Jr meeting with technocrats “creating wearable devices, AI tools, and personalized apps that empower Americans to take control of their health.” What all of this really does is allow for the mass collection of personal health data so that even more accurate health models can be created in order to personalized marketing and products that can be sold directly to the public with no middle party, while also empowering insurance companies to take advantage of knowing who can be charged more for private decisions. This isn't revolution, it's commodification and monetization. And at the very least, anyone advocating for methylene blue, itself a “fetotoxic agent,” or nicotine pouches without first examining all the free ways we can be healthier, or without noting that the first is a dye and the second is sold by a famously corrupt and evil industry, is either untrustworthy, ignorant, or a sell out. *The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.-FREE ARCHIVE (w. ads)SUBSCRIPTION ARCHIVEX / TWITTER FACEBOOKYOUTUBEMAIN WEBSITECashApp: $rdgable Paypal email rdgable1991@gmail.comEMAIL: rdgable@yahoo.com / TSTRadio@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-secret-teachings--5328407/support.

We have a special guest on today's episode whose voice will be familiar to regular listeners. Last year at this time, Dr. Raven Baxter occupied the Raise the Line host chair for a special ten-part series we produced in collaboration with the Cohen Center for Recovery from Complex Chronic Illness (CoRe) at Mount Sinai in New York City, where she serves as the Director of Science Communication. The series explored the latest understandings of post-acute infection syndromes -- such as Chronic Lyme and Long COVID -- with an array of experts from the Center and other researchers and providers. In this episode, we check-in with Dr. Baxter to get an update on the work of the Cohen Center, especially with regard to its mission to educate providers. “We're building programs so that clinicians can earn credit for learning about chronic illnesses that are infection associated, and we've also developed a 200-page provider manual. I really think that we will be able to shift the narrative that currently exists,” Dr. Baxter tells host Michael Carrese. That narrative includes lingering skepticism among providers of some infection-associated illnesses, which Dr. Baxter witnessed herself as a Long COVID patient, an experience that has added meaningful perspective to her work. Dr. Baxter is also working on her own time to advance knowledge and combat misinformation through a robust social media presence as “The Science Maven” and helps other scientists and clinicians to do the same. "If we're not there to fill in that void, other people will fill it for us and the narrative may not be consistent with the truth or facts." This is a great opportunity to learn about the art and science of communications that can reach clinicians and patients alike.Mentioned in this episode:Cohen Center for Recovery from Complex Chronic IllnessThe Science Maven If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

EPISODE DESCRIPTIONLisa Shufro is the storyteller's storyteller. A musician turned innovation strategist, TEDMed curator, and unapologetic truth-teller, Lisa doesn't just craft narratives—she engineers constellations out of chaos. We go way back to the early TEDMed days, where she taught doctors, scientists, and technocrats how not to bore an audience to death. In this episode, we talk about how storytelling in healthcare has been weaponized, misunderstood, misused, and still holds the power to change lives—if done right. Lisa challenges the idea that storytelling should be persuasive and instead argues it should be connective. We get into AI, the myth of objectivity, musical scars, Richard Simmons, the Vegas healthcare experiment, and the real reason your startup pitch is still trash. If you've ever been told to “just tell your story,” this episode is the permission slip to do it your way. With a bow, not a violin.RELATED LINKSLisa Shufro's WebsiteLinkedInSuper Curious ArchiveEight Principles for Storytelling in InnovationStoryCorps InterviewCoursera Instructor ProfileWhatMatters ProjectFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

⚠️ Content Warning: This episode contains a discussion around suicidal thoughts. Please take care while listening and seek support if you need it.Living with Complex Regional Pain Syndrome (CRPS) isn't just painful—it's punishing. It hijacks your body, messes with your mind, and turns everyday tasks into uphill battles. In this episode, Lyndsay Soprano sits down with Jeannette Tashjian for a brutally honest conversation about what it really means to live with relentless, unpredictable pain.They talk about the parts most people don't see: the mental spiral, the isolation, the weight of explaining yourself over and over, and the moments when giving up feels like the only option. But they also talk about what keeps them going—connection, infrared sauna therapy, self-advocacy, and the power of simply being heard.This episode doesn't sugarcoat anything. From navigating life with a disability to confronting the stigma around suicidal thoughts, Jeannette and Lyndsay lay it all out. They speak from the gut—about grief, about resilience, and about finding pieces of joy in a body that feels like it's working against you.If you've ever felt like no one understands what you're going through—or if you love someone who lives with chronic pain—this conversation will hit home.Tune in for the truth behind CRPS, and the reminder that you're not alone in this fight.Find Jeanette Tashjian Online Here:Website: www.burbankinfraredsauna.comInstagram: @burbankinfraredsaunaPast Guest Episode 6: The Pain Game Podcast Episode 6Find The Pain Game Podcast Online Here:Website: thepaingamepodcast.comInstagram: @thepaingamepodcastFacebook: The Pain Game PodcastLinkedIn: Lyndsay SopranoYouTube: The Pain Game PodcastIF YOU'RE IN CRISIS:USA – Call or text 988 (24/7)Canada – Call: 1-833-456-4566 (24/7) | Text: 45645 (4 PM–12 AM EST)Episode Highlights:(00:00) Introduction to Chronic Pain and Trauma(03:12) Understanding Complex Regional Pain Syndrome (CRPS)(06:01) Personal Stories of Pain and Trauma(08:52) The Role of Infrared Sauna in Pain Management(12:11) Navigating Life with CRPS(14:58) Acceptance and Coping Mechanisms(18:07) The Importance of Community and Support(23:42) Finding Freedom in Acceptance(30:43) Navigating the Pain Journey(31:12) Addressing Suicidal Thoughts(43:45) The Importance of Hope and Support

Mariano Mattei is the Vice President of Cybersecurity and AI at Azzur Solutions, bringing over 30 years of expertise in cybersecurity, AI innovation, and software engineering. A Certified Chief Information Security Officer (CCISO), Mariano has led AI-driven transformations across Biotechnology, Pharmaceuticals, and Medical Device sectors, integrating AI into clinical trials, manufacturing automation, quality systems, and regulatory compliance frameworks (FDA 21 CFR Part 11, GAMP 5, GDPR, HIPAA). His work spans predictive analytics for risk management, AI-powered process optimization, anomaly detection in manufacturing, and regulatory AI governance. He recently graduated from Temple University's Master's Program in Cyber Defense and Information Assurance, and he's the author of "Data-Driven Cybersecurity – Proven Metrics for Reducing Cyber Risk"Listen NOW to discover, "The Secret to Taking A Secure Risk"

What happens when you blend the soul of Mr. Rogers, the boldness of RuPaul, and just a pinch of Carrie Bradshaw? You get Sally Wolf.She's a Harvard and Stanford powerhouse who ditched corporate media to help people actually flourish at work and in life—because cancer kicked her ass and she kicked it back, with a pole dance routine on Netflix for good measure.In this episode, we unpack what it means to live (really live) with metastatic breast cancer. We talk about the toxic PR machine behind "pink ribbon" cancer, how the healthcare system gaslights survivors when treatment ends, and why spreadsheets and dance classes saved her sanity. Sally doesn't just survive. She rewrites the script, calls out the BS, and shows up in full color.If you've ever asked “Why me?”—or refused to—this one's for you.RELATED LINKS:Sally Wolf's WebsiteLinkedInInstagramCosmopolitan Essay: "What It's Like to Have the 'Good' Cancer"Oprah Daily Article: "Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis"Allure Photo ShootThe Story of Our Trauma PodcastFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

- Interview with Diane Keyser on Healing and Natural Beauty (0:11) - Special Report on MSG Toxicity (0:54) - Engineer Recruitment and Project Delays (2:20) - Spiritual Reflections and Personal Anecdotes (5:36) - Joe Biden's Prostate Cancer Diagnosis and Second Amendment Victory (9:17) - Challenges in Health and Nutrition (10:04) - Exploring Different Belief Systems (20:07) - Experiments and Demonstrations (24:15) - The War on Cognition and MSG Toxicity (57:19) - Hidden Sources of MSG in Food (1:09:20) - Fast Food Chains and MSG (1:18:57) - Fast Food and MSG: A Comprehensive Overview (1:24:49) - Health Consequences of MSG (1:27:10) - Comparing Fast Food to Packaged Grocery Store Food (1:28:48) - The History and Impact of MSG (1:31:55) - Cultural and Historical Context of MSG (1:34:21) - Personal Experiences and Advocacy (1:37:57) - The Role of Peptides in Health and Wellness (2:10:21) - The Science Behind Peptides (2:12:25) - Practical Applications and Personal Testimonies (2:13:39) - The Future of Peptides and Health Advocacy (2:13:53) - Body as a Molecular Factory (2:14:47) - Peptides and Their Miraculous Effects (2:43:11) - C Max and Its Cognitive Benefits (2:44:50) - Oxytocin and Its Role in Hormone Regulation (2:48:01) - Peptides vs. Pharmaceuticals (2:49:23) - BPC 157 and Its Benefits for Injuries (2:51:10) - Environmental Toxins and Their Impact on Health (2:56:18) - Personalized Peptide Therapy (3:05:05) - Injectable Peptides and Their Administration (3:08:05) - Conclusion and Call to Action (3:20:51) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com